2-Year Results of the AUTAX (Austrian Multivessel TAXUS-Stent) Registry

Gyöngyösi, Mariann; Christ, Günter; Lang, Irene M.; Kreiner, Gerhard; Sochor, Heinz; Probst, Peter; Neunteufl, Thomas; Badr-Eslam, R.; Winkler, Susanne; Nyolczas, Noémi; Pósa, Anikó; Leisch, F; Karnik, Ronald; Siostrzonek, Peter; Harb, Stefan; Heigert, Matthias; Zenker, G; Benzer, Werner; Bönner, G; Kaider, Alexandra; Glogar, Dietmar

doi:10.1016/j.jcin.2009.05.019

Cited by 13 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to our population profile, was a previous study done Robert et al, [20] mean age of the patients was 63 ± 12 years; the majority of the population was males (65%). The most prevalent coronary risk factor was hypertension (78%), dyslipidaemia (66%), and smoking 34%, diabetes mellitus 32%, their patients (32%) had an initial diagnosis of unstable angina, patients representing (41%) were initially diagnosed as ACS with ST elevation myocardial infarction, while NSTEMI in (23%).…”

Section: Discussionsupporting

confidence: 89%

“…No cases of instent thrombosis was detected in our study while it occurred in 1.7% of patients with in the Robert et al [20] , this may be due to the more usage of Paclitaxel eluting stent that was discovered later on that it was associated with increased risk of stent thrombosis.…”

Section: Discussioncontrasting

confidence: 40%

“…As you see in our study patient population were younger than done by Robert colleague [20] and this may be due to the increased percentage of the coronary artery disease.…”

Section: Discussionmentioning

confidence: 57%

“…Applegate, et al, [20] results at 2 years was the hazard ratio for DES compared with BMS for nonfatal MI or death was 0.77 (95% Confidence Interval [CI] 0.62 to 0.95), for all-cause mortality 0.71 (0.54 to 0.92), and Stent Thrombosis (ST) 0.97 (0.49 to 1.91). "On-label" stent procedures were associated with lower risk of MI, death, and ST than "off-label" stent procedures.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome

Gharib¹,

Elhossary

2021

The Medical Journal of Cairo University

View full text Add to dashboard Cite

Background: Drug-eluting stents are used in 80%. To 90% of revascularization procedures in the United States. Everolimus embedded in a durable polymer on a cobalt chromium Stent has shown superiority compared with Bare Metal Stents (BMS), and paclitaxel eluting stent for reduction of both late loss and binary restenosis. Aim of Study:To study the safety, efficacy and acute angiographic outcome of the new Everolimus Eluting Stent in correlation with short-term clinical follow-up in patient with Acute Coronary Syndrome (ACS).Patients and Methods: A prospective study in which ninety-five patients with (ACS), Scheduled for PCI in the cardiac catheterization laboratory in Cairo University Hospitals or NHI, using Everolimus DES, were enrolled from Jan. 2009 to June 2009. Their clinical, angiographic, interventional and follow-up data were collected and analyzed.Results: Acute success was achieved in all the cases with no device failure, after six month of follow-up, patients (94.5%) had expressed no events or chest pain, 1 patient had stable angina and refused to redo the coronary angiography, 3 patients had redo the coronary angiography due to recurrent chest pain (two of them had redo PCI in remote vessel and the other had no significant lesion), and 1 patient died because of retroperitoneal hematoma. Conclusion:The everolimus eluting stent are a safe type of drug eluting stent in clinical Practice with favorable short term outcomes in patients with acute coronary syndromes.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussioncontrasting

confidence: 40%

“…As you see in our study patient population were younger than done by Robert colleague [20] and this may be due to the increased percentage of the coronary artery disease.…”

Section: Discussionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome

Gharib¹,

Elhossary

2021

The Medical Journal of Cairo University

View full text Add to dashboard Cite

show abstract

“…The reduced costs from fewer TVR (which is further reduced by using the currently cheaper DES) seem to balance the higher initial costs of DES, reducing the long‐term clinical and economic advantages of CABG. Moreover, TVR belongs to the so‐called “soft” adverse events, as no evidence has shown that it influences mortality .…”

Section: Discussionmentioning

confidence: 99%

Cost‐effectiveness of percutaneous coronary intervention with drug‐eluting stents in patients with multivessel coronary artery disease compared to coronary artery bypass surgery five‐years after intervention

Krenn

Kopp

Glogar

et al. 2014

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

ObjectivesCost-effectiveness of percutaneous coronary intervention (PCI) using drug-eluting stents (DES), and coronary artery bypass surgery (CABG) was analyzed in patients with multivessel coronary artery disease over a 5-year follow-up.BackgroundDES implantation reducing revascularization rate and associated costs might be attractive for health economics as compared to CABG.MethodsConsecutive patients with multivessel DES-PCI (n = 114, 3.3 ± 1.2 DES/patient) or CABG (n = 85, 2.7 ± 0.9 grafts/patient) were included prospectively. Primary endpoint was cost-benefit of multivessel DES-PCI over CABG, and the incremental cost-effectiveness ratio (ICER) was calculated. Secondary endpoint was the incidence of major adverse cardiac and cerebrovascular events (MACCE), including acute myocardial infarction (AMI), all-cause death, revascularization, and stroke.ResultsDespite multiple uses for DES, in-hospital costs were significantly less for PCI than CABG, with 4551 €/patient difference between the groups. At 5-years, the overall costs remained higher for CABG patients (mean difference 5400 € between groups). Cost-effectiveness planes including all patients or subgroups of elderly patients, diabetic patients, or Syntax score >32 indicated that CABG is a more effective, more costly treatment mode for multivessel disease. At the 5-year follow-up, a higher incidence of MACCE (37.7% vs. 25.8%; log rank P = 0.048) and a trend towards more AMI/death/stroke (25.4% vs. 21.2%, log rank P = 0.359) was observed in PCI as compared to CABG. ICER indicated 45615 € or 126683 € to prevent one MACCE or AMI/death/stroke if CABG is performed.ConclusionsCost-effectiveness analysis of DES-PCI vs. CABG demonstrated that CABG is the most effective, but most costly, treatment for preventing MACCE in patients with multivessel disease. © 2014 Wiley Periodicals, Inc.

show abstract

Predictive Accuracy of SYNTAX Score for Predicting Long-Term Outcomes of Unprotected Left Main Coronary Artery Revascularization

Chakravarty

Buch

Naik

et al. 2011

The American Journal of Cardiology

View full text Add to dashboard Cite

2-Year Results of the AUTAX (Austrian Multivessel TAXUS-Stent) Registry

Cited by 13 publications

References 23 publications

Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome

Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome

Cost‐effectiveness of percutaneous coronary intervention with drug‐eluting stents in patients with multivessel coronary artery disease compared to coronary artery bypass surgery five‐years after intervention

Predictive Accuracy of SYNTAX Score for Predicting Long-Term Outcomes of Unprotected Left Main Coronary Artery Revascularization

Contact Info

Product

Resources

About